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Ethnopharmacological  relevance:  Uncaria  tomentosa  (Willd.)  DC (Rubiaceae)  is  a species  native  to  the  Ama-
zon  rainforest  and  surrounding  tropical  areas  that  is  endowed  with  immunomodulatory  properties  and
widely used  around  the  world.  In this  study  we investigated  the  immunomodulatory  potential  of  Uncaria
tomentosa  (UT)  aqueous–ethanol  extract  on  the  progression  of  immune-mediated  diabetes.
Materials  and  methods:  C57BL/6  male  mice  were  injected  with  MLDS  (40  mg/kg)  and  orally  treated
with  UT  at  10–400  mg/kg  during  21  days.  Control  groups  received  MLDS  alone  or the  respective
dilution vehicle.  Pancreatic  mononuclear  inﬁltrate  and  -cell  insulin  content  were  analyzed  by  HE
and  immunohistochemical  staining,  respectively,  and  measured  by  digital  morphometry.  Lymphocyte
immunophenotyping  and  cytokine  production  were  determined  by  ﬂow  cytometry  analysis.
Results:  Treating  the  animals  with  50–400  mg/kg  of UT caused  a signiﬁcant  reduction  in the  glycemic
levels,  as  well  as in the  incidence  of diabetes.  The  morphometric  analysis  of insulitis  revealed  a  clear
protective  effect.  Animals  treated  with  UT at 400  mg/kg  presented  a higher  number  of  intact  islets  and
a signiﬁcant  inhibition  of  destructive  insulitis.  Furthermore,  a signiﬁcant  protection  against  the loss  of
insulin-secreting  presented  -cells  was  achieved,  as  observed  by  a careful  immunohistochemical  eval-
uation.  The  phenotypic  analysis  indicated  that  the  groups  treated  with  higher  doses  (100–400  mg/kg)
presented  CD4+ and  CD8+ T-cell  values  similar  to those  observed  in  healthy  animals.  These  same  higher
doses  also  increased  the number  of CD4+CD25+Foxp3+ regulatory  T-cells.  Moreover,  the  extract  modu-
lated  the  production  of  Th1  and  Th2,  with  increased  levels  of IL-4  and IL-5.
Conclusions:  The  extract  was  effective  to prevent  the  progression  of  immune-mediated  diabetes  by  dis-
tinct  pathways.
. Introduction
Immuno-mediated diabetes mellitus is a chronic disease with
ultifactorial etiology and whose incidence is exponentially
ncreasing in developed nations since the 1950s (Lévy-Marchal
t al., 1995; Zipris, 2009). The early stage of the disease is
haracterized by an inﬂammatory mononuclear inﬁltration into
ancreatic islets, with the progressive loss of insulin-secreting -
ells (Atkinson and Eisenbarth, 2001). Although both humoral and
ellular mechanisms are activated during the progression of the dis-
ase CD4+ and CD8+ T cells seem to be important ﬁnal effectors of
∗ Corresponding author. Tel.: +55 021 14 3811 6238; fax: +55 021 14 3815 2348.
E-mail address: domingues1@gmail.com (A. Domingues).
378-8741 © 2011 Elsevier Ireland Ltd. 
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-cell death (Pearl-Yafe et al., 2007). It has been demonstrated that
the severity of insulitis is closely related to an increased expression
of pro-inﬂammatory cytokines such as IFN- and TNF- and a con-
comitant reduction in IL-4, IL-5 and IL-10 levels (Rabinovitch and
Suarez-Pinzon, 1998). Furthermore, a fundamental role has been
attributed to CD4+CD25+Foxp3+ regulatory T (Treg) cells on the reg-
ulation of immune tolerance and the self-reactive response during
the progress of this disease (Chen et al., 2005; Wing and Sakaguchi,
2010).
In susceptible strains of mice, immune-mediated diabetes can
be induced by multiple low-doses of streptozotocin (MLDS) (Reddy
Open access under the Elsevier OA license. et al., 2008; Lin et al., 2010). This model is quite different from
the type 2 diabetes model induced by a single high dose of
streptozotocin. Several studies have shown that the injection of
MLDS trigger an immune-mediated disorder characterized by a
6 hnopharmacology 137 (2011) 635– 642
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Fig. 1. Experimental protocol. Diabetes was induced by ﬁve sub-diabetogenic doses
of  streptozotocin or its dilution vehicle as follows. G1: alcohol 10% and citrate buffer;
G2:  Uncaria tomentosa extract 400 mg/kg and citrate buffer; G3: MLDS 40 mg/kg
and  alcohol 10%; G4–G7: MLDS 40 mg/kg and Uncaria tomentosa extract at 10, 50,36 A. Domingues et al. / Journal of Et
ononuclear inﬂammatory inﬁltrate within the pancreatic islets
nd the progressive loss of functional -cells through the activ-
ty of self-reactive Th1 cells, macrophages and pro-inﬂammatory
ytokines such as IFN- (Cetkovic-Cvrlje and Uckun, 2005). Periph-
ral changes such as downregulation of Th2-derived cytokines and
nhibition of Treg cells were also demonstrated (Zdravkovic et al.,
009). One of the advantages of this model is the fact that hyper-
lycemia and insulitis are observed in a relatively short period of
ime (2–3 weeks after the last STZ injection) in a high percentage
f animals (Paik et al., 1980; Santos et al., 2009).
In this sense, ideal immune-based interventions should be ini-
iated before the onset of the disease or, at least, during the period
hen a reasonable number of -cells is still present in the pancreas.
herefore, herbal immunomodulators could provide an interesting
ool to prevent or to reduce the destruction of islet cells through
he dynamic modulation of immunological functions.
Uncaria tomentosa (Willd.) DC (Rubiaceae), known as cat’s claw,
s a species native to the Amazon rainforest and surrounding trop-
cal areas that is endowed with immunomodulatory properties.
hese properties include modulation of the cytokines TNF-, IL-
 and IL-6 (Lemaire et al., 1999; Allen-Hall et al., 2007, 2010),
nhancement of phagocytosis (Wagner et al., 1985), regulation of
NOS and NF-B expression (Sandoval-Chacón et al., 1998) and
he inhibition of lymphocyte proliferation (Akesson et al., 2003;
inkler et al., 2004). More recently, Reis et al. (2008) reported that
he alkaloid fraction from Uncaria tomentosa bark caused a strong
nhibition of TNF- and IFN- production by human monocytes
hat were infected with type-2 Dengue virus. So far, the chemical
nalysis of the species revealed the presence of indole and oxindole
lkaloids, proanthocyanidins, sterols, triterpenoids and carboxyl-
lkyl esters (Sandoval et al., 2000; Akesson et al., 2005; Gonc¸ alves
t al., 2005; Heitzman et al., 2005). Individually or synergistically,
hese compounds contribute to the therapeutic properties of the
pecies.
The present work was based on the hypothesis that the
mmunomodulatory properties of Uncaria tomentosa could prevent
-cell mass loss and therefore delay diabetes progression. We  eval-
ated the effect of a chemically deﬁned hydroethanolic extract of
ncaria tomentosa bark on diabetes development, cytokine produc-
ion and number of peripheral Foxp3+ Treg cells by employing the
lassic MLDS immune-mediated diabetes model.
. Materials and methods
.1. Plant material and extract chemical proﬁle
An aqueous–ethanol 1:1 extract that was previously obtained
Valente et al., 2006) from the stem bark of a wild specimen of
ncaria tomentosa,  collected in Cruzeiro do Sul, Acre, Brazil, and
onated by Biosapiens Co., Brazil (voucher data in Miranda et al.,
003), was used for the assays. The pentacyclic oxindole alkaloid
POA) proﬁle and content of this extract was determined using
igh-performance liquid chromatography (HPLC–UV-DAD–MS) as
reviously described (Pereira et al., 2008; Reis et al., 2008).
rieﬂy, an alkaloid enriched fraction was obtained through clas-
ical acid–base partition from this aqueous–ethanol extract. The
entacyclic oxindole alkaloids (POA) present were identiﬁed by
sing a Lichrocart Lichrospher 5 m,  125 mm × 4.6 mm i.d. col-
mn  and UV-detector at 245 nm under the same conditions
escribed by Laus and Keplinger (1994).  The identiﬁcation of the
OA signals was made by comparison of their relative reten-
ion times to pteropodine with those described. In addition, the
raction was submitted to HPLC-DAD–MS analysis in the same
hromatographic column using a mixture of 45% of CH3CN/55%
f aqueous 30 mM NH4OAc solution, pH adjusted at 6.8–7.0 as100 or 400 mg/kg, respectively. n = 8 animals/group. Uncaria tomentosa extract or its
dilution vehicle (alcohol 10%) was administered by oral route. MLDS or its dilution
vehicle (citrate buffer) was injected by intraperitoneal route.
mobile phase, isocratic mode, ﬂow rate of 1.0 mL/min, at 60 ◦C
and detection at 245 nm in order to monitor the ion [M+1]+ at
m/z 369 (Lopez-Avila et al., 1997) and the corresponding UV
spectra (Mazzei, 2004). The determination of the total alkaloid con-
tent was achieved by HPLC–UV under the latter chromatographic
conditions through external standardization relative to isopteropo-
dine.
2.2. Animals
Six weeks old pathogen-free C57BL/6 male mice were purchased
from the Multidisciplinary Center of Biological Investigations
(CEMIB, Campinas, São Paulo, Brazil) and housed in controlled envi-
ronmental conditions (temperature 22 ± 2 ◦C, relative humidity
55 ± 20%, 12/12 h light–dark cycle and 4 daily exhaustion periods).
All animals received Nuvilab CR-1 commercial food (Nuvital, Brazil)
and water ad libitum and were submitted to a 2-week acclima-
tion period before the experiment. Experimental protocols were
approved by the Committee for Ethics in Animal Experimentation
of the UNESP Medical School, São Paulo, Brazil (protocol number
635).
2.3. Diabetes induction and experimental design
The animals were randomized in groups of eight, according
to the protocol presented in Fig. 1. Experimental diabetes was
induced by ﬁve intraperitoneal (i.p) injections of streptozotocin
(Sigma–Aldrich, St. Louis, MO,  USA) at 40 mg/kg, during 5 consec-
utive days (Fallarino et al., 2010). Uncaria tomentosa extract was
given by gavage during 21 consecutive days, beginning at the ﬁrst
streptozotocin injection. A control group injected with the strepto-
zotocin vehicle (citrate buffer, pH 4.5) was  treated with the Uncaria
tomentosa diluent (alcohol 10%). Blood samples were collected from
the retro-orbital plexus and glucose concentration was  assessed on
days 0, 12 and 21, using the Prestige LX Smart System Test-strips
(Home Diagnostic Inc., Fort Lauderdale, USA). Glucose levels of
200 mg/dL (12 mmol/L) or above indicated diabetes development.
At the end of the experiment, the animals were euthanized in a CO2
chamber and blood and tissue samples were collected.
2.4. Tissue processing and histological analysis
Pancreas, liver, kidneys, spleen, thymus, mesenteric lymph
nodes and femur were removed and ﬁxed in buffered formalin
10% (phosphate buffer pH = 7.2) (Carlo Erba Reagents, Milano, Italy)
for 24 h. The spleen was  divided into two portions: one for his-
tology and the other for lymphocyte phenotypic analysis by ﬂow
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ytometry. The parafﬁn blocks were cut into 5-m-thick sections
nd stained with hematoxylin–eosin (HE) (Sigma–Aldrich, USA).
he histophatological analysis was conducted following previously
uidelines by the Society of Toxicologic Pathology (Haley et al.,
005).
.5. Morphometric analysis of pancreatic insulitis
A quantitative evaluation of islet mononuclear inﬁltration was
onducted using a computer-assisted image system based on a
ikon Microphot-FXA optical microscope connected via a Sony
xwave HAD video camera to a computer. To avoid inter-animal
ariance due to pancreatic endocrine heterogeneity, total section
rea of each pancreas was measured and sectioned throughout its
ength in ﬁve sections, sampled at regular intervals of 50 m.  Islets
ere traced manually and islet area was measured and expressed
s a fraction of total section area.
Further, islet and inﬂammation areas were measured individu-
lly, as described elsewhere (Kauri et al., 2007), using the KS300
oftware (Carl-Zeiss, AG, Germany). The result was expressed
s the percentage of islet area showing mononuclear cell inﬁl-
ration, according to the formula: mononuclear inﬁltrate area
m2) × 100/islet area (m2). Finally, the results were catego-
ized into the following score: 0 = intact islet; 1 = peri-insulitis
≤10% of the islet inﬁltrated); 2 = moderate insulitis (≤50% of
he islet inﬁltrated); 3 = severe insulitis (≥50% of the islet inﬁl-
rated); and 4 = destructive insulitis (Santos et al., 2009). At least
0 islets per pancreas were analyzed in non-consecutive sec-
ions. To evaluate the protective effect of the extract against the
oss of endocrine tissue, islets were manually traced and classi-
ed as small (300–2000 m2), medium (2000–10,000 m2), large
10,000–50,000 m2) and very large (>50,000 m2) (Kauri et al.,
007).
.6. In situ insulin detection
Islet insulin content was evaluated by the avidin–biotin per-
xidase complex (ABC) method as previously described (Pinheiro
t al., 2003). Brieﬂy, deparafﬁnated 5-m tissue sections on poly-l-
ysine-coated slides were treated with 0.01 M citrate buffer (pH 6.0)
nd heated twice, 5 min  each time, in a microwave oven. To block
onspeciﬁc background staining, the sections were treated with
% H2O2 in phosphate-buffered saline (PBS) for 10 min  and non-fat
ilk for 60 min. The slides were then incubated with polyclonal
uinea pig anti-insulin antibody (dilution 1:500, Dako Glostrup,
enmark) overnight and then with rabbit anti-guinea pig IgG
oupled with peroxidase (Dako, Glostrup, Denmark). Chromogen
olor development was accomplished with 3,3′-diaminobenzidine
etrahydrochroride (Sigma). The slides were counterstained with
arris’s hematoxylin. The morphometric analysis was performed
sing computer-assisted image system, as described in Section 2.5.
slet insulin content was established by calculating the area of
mmunopositive insulin relative to the islet’s area, according to the
ormula: insulin positive area (m2) × 100/islet area (m2).
.7. Splenic cell suspensions
Spleens were pushed against a 50 m sterile nylon mesh
BD, New Jersey, USA) in Petri dishes containing RPMI-1640 cul-
ure medium (Cultilab, Campinas, Brazil) and the erythrocytes
ere lysed with an isotonic solution of ammonium chloride,
otassium bicarbonate and ethylenediamine tetraacetic acid (pH
.2) (Sigma–Aldrich, USA). Cell suspensions were washed twice
200 × g/10 min), and the pellet was re-suspended in RPMI-1640
ulture medium that was supplemented with 10% inactivated
ovine fetal serum (Cultilab, Campinas, Brazil). Cellular viabilityarmacology 137 (2011) 635– 642 637
was checked using trypan blue (Hyclone, Thermo Scientiﬁc, USA)
and was considered adequate for values greater than 90%. Cell
suspensions were adjusted to 1 × 106 or 5 × 106 cells/mL for sub-
sequent phenotypic analysis and cytokine evaluation, respectively.
2.8. Lymphocyte immunophenotyping by ﬂow cytometry
Splenocyte suspensions, obtained as described in Section 2.7,
were adjusted to 1 ×106 cells/mL and aliquots (100 L) were trans-
ferred to 12 mm ×75 mm polypropylene round bottom test tubes
(BD Pharmingen, San Diego, CA, USA). The samples were incubated
in the dark with FITC rat anti-mouse CD4 (L3T4-clone) and PE-
Cy5 rat anti-mouse CD8a (Ly-2 clone) (BD Pharmingen, San Diego,
CA, USA). After 30 min, the samples were washed twice (200 × g
during 10 min) and re-suspended in 400 L of cold ﬂow cytome-
try staining buffer (BD Pharmingen, San Diego, CA, USA). For the
analysis of regulatory T cells, 100 L of the splenocyte suspen-
sion (1 × 106 cells/mL) was  incubated with FITC rat anti-mouse CD4
and PE-Cy7 rat anti-mouse CD25 following the same conditions
described above. After the washing step, the pellet was submitted
to a ﬁxation/permeabilization solution (Ebioscience, San Diego, CA,
USA) according to the manufacture’s instruction and incubated in
the dark for 30 min  with PE labeled anti-mouse Foxp3 (Ebioscience,
San Diego, CA, USA). The samples were washed twice (200 × g,
10 min) and the pellet was  re-suspended in 400 L of cold ﬂow
cytometry staining buffer. Lymphocyte subsets were determined
by FACS Calibur analysis (BD, New Jersey, USA), with gating on
the total lymphocyte population. For consistency, a standard cal-
ibration bead (BD Pharmingen, New Jersey, USA) was used to set
the forward scatter, side scatter and PMT  voltage. For each exper-
imental sample, a corresponding isotype control was  used to set
gates on positive/negative cell populations. The data were repre-
sented as the percentage of positive marked cells in their respective
gates.
2.9. Th1 and Th2 cytokine production
Splenocytes obtained as described in Section 2.7 were dispensed
in a 48-wells ﬂat bottomed tissue culture plate (Corning, Costar,
USA) at 5 × 106 cells/mL (450 L). The samples were stimulated
with Con A (10 g/mL) and the plates were incubated for 48 h
(37 ◦C, 5% CO2). The supernatants were then collected and stored
at −80 ◦C. Th1 and Th2 cytokines were quantiﬁed using a murine
Th1/Th2 cytometric bead array (CBA) kit according to the manufac-
turer’s instructions (BD Pharmingen, USA). The FACS Calibur ﬂow
cytometer (BD Pharmingen, USA) was calibrated using setup beads,
and a total of 3000 events were acquired for each sample. Indi-
vidual cytokine concentrations (pg/mL) were evaluated by their
ﬂuorescence intensities and analyzed based on the standard ref-
erence curve of CELLQUEST and CBA software (BD Pharmingen,
USA).
2.10. Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0.
Data were tested for normality (Kolmogorov–Smirnov) and homo-
geneity (Bartlett’s) and, when necessary, submitted to appropriate
transformations. Body weight, water and food intake, organ weight,
hematological parameters, immunophenotyping, cytotoxicity data
and cytokine concentration were compared by ANOVA. When
ANOVA results were signiﬁcant (p < 0.05), the comparison was
followed by the Tukey test. For the non-parametric data, the
Kruskal–Wallis test was  applied. Glycemic levels were analyzed by
Friedman test.
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Fig. 2. HPLC–UV pentacyclic oxindole alkaloid proﬁle (Laus and Keplinger, 1994
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Fig. 3. Effect of Uncaria tomentosa extract on glycemic levels and diabetes incidence.
(a)  Uncaria tomentosa extract determined a signiﬁcant reduction of glycemic levels
(mean ± SD). *,**Signiﬁcantly higher than the observed in G1 and G2 groups; p < 0.05
and p < 0.001, respectively. #, ##Signiﬁcantly lower than the observed in G3 group;
p  < 0.01 and p < 0.001, respectively. (b) Uncaria tomentosa extract delayed diabetes
incidence. Values are expressed as percentage of diabetic animals. G1 and G2: neg-
T
Ionditions) of the studied Uncaria tomentosa alkaloidal fraction. (1) Specio-
hylline; (2) mitraphylline; (3) uncarine F; (4) pteropodine; (5) isomitraphylline;
6) isopteropodine. For extract quantiﬁcation details see Reis et al. (2008).
. Results
.1. Pentacyclic oxindole alkaloid proﬁle and content
The previous HPLC analysis (Pereira et al., 2008; Reis et al., 2008)
f this bioactive aqueous–ethanol extract of Uncaria tomentosa indi-
ated the presence of the six pentacycle oxindole alkaloid that were
onsidered to be chemical markers of the species: speciophylline,
itraphylline, uncarine F, pteropodine, iso-mitraphylline and iso-
teropodine (Fig. 2). The total alkaloid content, usually the marker
or assessing the pharmaceutical quality of the cat’s claw extracts,
as 29.1 mg/g (±1%) which is in agreement with commercially
cceptable plant materials.
.2. Effect of Uncaria tomentosa on the incidence of diabetes
As expected, inoculation with MLDS was associated with a
uccessful diabetes induction, characterized by high glucose con-
entrations. Mice injected with MLDS presented glycemic levels
igniﬁcantly higher at experimental days 12 and 21. Treatment
ith 80, 100 and 400 mg/kg of the Uncaria tomentosa extract deter-
ined a signiﬁcant reduction in the glycemic levels at the end of
he experimental period (Fig. 3a).
All tested doses (10–400 mg/kg) promoted a delay in diabetes
ncidence during the experimental period and, furthermore, the
ighest Uncaria tomentosa dose completely abrogated diabetes
ncidence at day 12, preventing the raise of glycemic levels above
00 mg/dL in most of the animals at day 21 (Fig. 3b).
.3. Histopathology and morphometric analysis of insulitis and
nsulin contentThe histological analysis of spleen, lymph nodes, kidneys, thy-
us, femur and liver did not reveal signiﬁcant structural differences
mong the untreated and treated groups.
able 1
slet sizea in C57BL/6 mice injected with MLDS and orally treated with the aqueous–etha
Small (<2000 m2) Medium (<10,0
G1 – negative control 0 15 
G2  – UT 400 mg/kg 0 20 
G3  – MLDS control 42 48 
G4  – MLDS + UT 10 mg/kg 25 61 
G5  – MLDS + UT 50 mg/kg 16 67 
G6  – MLDS + UT 100 mg/kg* 0 40 
G7  – MLDS + UT 400 mg/kg* 0 15 
a Islet size was  measured using a computer-assisted image system and expressed as re
* Groups G6 and G7 presented islet size signiﬁcantly higher than the observed in G3 grative  control and Uncaria tomentosa at 400 mg/kg, respectively; G3: MLDS control;
G4–G7: MLDS + Uncaria tomentosa at 10, 50, 100 and 400 mg/kg, respectively.
As expected, animals injected with MLDS presented a clear
pattern of insulitis, with the predominance of moderate (grade
2) and invasive (grade 3) insulitis. At the highest experimental
dose (400 mg/kg), Uncaria tomentosa extract produced a signif-
icant protection against mononuclear inﬁltration, characterized
by the higher percentage of intact islets (grade 0) and a con-
comitantly reduction in the percentage of moderate, severe
and destructive insulitis (Fig. 4a). These effects were accom-
panied by preventive reduction in islet size determined by
MLDS, resulting in a predominance of medium and large islets
(Table 1). Reduced frequency of apoptotic bodies, cytoplasmatic
vacuolization and eosinophilia were also observed, reinforc-
ing a protective effect against destructive insulitis (data not
showed).
As expected, insulin production by -cells was clearly reduced in
animals injected with MLDS (Fig. 4b). However, the Uncaria tomen-
tosa treatment, particularly at 400 mg/kg, promoted the highest
preservation in the insulin content in situ (Fig. 4c–e).
nol extract of Uncaria tomentosa during 21 days.
00 m2) Large (<50,000 m2) Very large (>50,000 m2)
75 10
66 14
10 0
14 0
17 0
48 12
71 14
lative values (%) for each experimental group.
oup (p < 0.001–chi-square test).
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Fig. 4. Protective effect of Uncaria tomentosa extract on the incidence of insulitis (a) and insulin production (b). *Higher number of intact islets (Grade 0) when compared to
G3  group (p < 0.05, chi-square test). #Signiﬁcantly different from G1 and G2 control groups (p < 0.001). Figures (c)–(e) indicated in situ insulin content. (c) G1 control group,
(d)  G3 MLDS group and (e) G7 Uncaria tomentosa extract 400 mg/kg group, respectively. G1 and G2: negative control and Uncaria tomentosa extract 400 mg/kg, respectively;
G /kg, re
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Animals injected with MLDS produced a Th1 cytokine proﬁle,
T
P
23:  MLDS control; G6 and G7: MLDS + Uncaria tomentosa extract at 100 and 400 mg
.4. Phenotypic analysis of splenic lymphocyte subsets
Animals injected with MLDS presented a reduced number of
D4+ T cells. However, treatment with Uncaria tomentosa extract at
00 and 400 mg/kg determined a signiﬁcant increase in the number
f CD4+ T cells. The phenotypic analysis did not reveal signiﬁ-
ant difference regarding the percentage of CD8+ T cells among
he groups (Table 2). Injection of MLDS also reduced the percent-
ge of CD4+CD25+Foxp3+ Treg lymphocytes. However, treatment
ith Uncaria tomentosa extract at 100 and 400 mg/kg resulted in
able 2
henotypic analysisa of splenic lymphocyte subsets in C57BL/6 mice injected with MLDS 
1  days.
CD4+ cells 
G1 – negative control 24.22 ± 1.1 
G2  – UT 400 mg/kg 23.0 ± 1.1 
G3  – MLDS control 18.82 ± 0.6*
G4 – MLDS + UT 100 mg/kg 24.26 ± 1.6 
G5  – MLDS + UT 400 mg/kg 23.2 ± 1.5 
a Values are expressed as percentage of lymphocyte subsets (mean ± SD), 10,000 cells/a
* Signiﬁcantly different from G1 group, p < 0.05.spectively.
Treg cell values similar to those observed in the control groups
(Table 2).
3.5. Effect of Uncaria tomentosa extract on Th1/Th2 cytokine
productioncharacterized by higher IFN- levels and a non-signiﬁcant decrease
of IL-4 and IL-5 levels, in comparison to the control groups. On
the other hand, treatment with Uncaria tomentosa prevented this
and orally-treated with the aqueous–ethanolic extract of Uncaria tomentosa during
CD8+ cells CD4+CD25+Foxp3+ Tregs
15.2 ± 2.5 3.2 ± 0.3
14.5 ± 0.9 3.0 ± 0.6
12.5 ± 0.4 2.3 ± 0.4*
15.4 ± 3.5 2.7 ± 0.6
14.9 ± 0.6 2.9 ± 0.5
nimals were counted.
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h1 polarization and also determined a signiﬁcant increase in IL-4
roduction (Fig. 5).
. Discussion
Immune-mediated diabetes is a chronic disorder associated,
n genetically susceptible individuals, with generation and activa-
ion of autoreactive T cells (Chentouﬁ et al., 2008). Experimental
mmunotherapies for the disease involve a broad spectrum of
mmunoregulatory strategies, including deletion of lymphocyte
ubsets or the use of substances that induce immune tolerance
hrough T regulatory (Treg) cells activation (Kohm et al., 2005;
hung et al., 2007). Some of these approaches have shown efﬁcacy
n clinical trials, but risks such as abnormal cytokine release and/or
eactivation of latent viruses render difﬁcult its adoption (Luo et al.,
010). In this context, herbal immunomodulators could be con-
idered potential adjuvant therapies. Uncaria tomentosa is being
argely used as antitumoral, antioxidant and immunomodulatory
gents (Allen-Hall et al., 2010; Dreifuss et al., 2010). Our study is
he ﬁrst to demonstrate that an aqueous–ethanolic Uncaria tomen-
osa extract was able to prevent the full evolution of experimental
iabetes. Immune-mediated diabetes was induced by injecting
57BL/6 mice with multiple low streptozotocin doses (MLDS dia-
etes). This procedure has been reported as capable to initiate
 minor chemical destruction of  cells and shedding of islet’s
elf-antigens. As a consequence, immune cells respond to -cell
elf-antigens and the progression of hyperglycemia and insulitis
volve during a 2-week period (Cvjetic´anin et al., 2010). This MLDS
odel has been largely employed to study the immunological
echanisms underlying diabetes, including its immunopathogen-sis and also therapeutic strategies (Karabatas et al., 2005; Kanitkar
t al., 2008).
Many parameters sustained the protective effect of Uncaria
omentosa against the progression of diabetes in the MLDS model.
ig. 5. Effect of Uncaria tomentosa extract on the mitogen-induced Th1 and Th2 cytokine p
rom  G3 group, p < 0.05. G1 and G2: negative control and Uncaria tomentosa 400 mg/kg, re
nd  400 mg/kg, respectively.armacology 137 (2011) 635– 642
We  initially observed that all tested doses were able to decrease
glycemic levels. This effect was already observed at experimen-
tal day 12 but was  more pronounced at day 21. Moreover, this
activity showed to be dose-dependent; the highest concentration
being the most efﬁcient one. Notably, the highest Uncaria tomen-
tosa dose (400 mg/kg) was  able to reduce the diabetes incidence
to 15%, whereas the STZ non-treated group displayed 100% of dia-
betes incidence. Similar hypoglycemic activity has been attributed
to other plant-derived natural products, such as Cassia auricu-
lata and Bauhinia forﬁcata (Gupta et al., 2009; Da Cunha et al.,
2010). This protective potential has been associated with diverse
mechanisms such as restoration of pancreatic function, increase in
insulin release and inhibition of glucose intestinal absorption (Jia
et al., 2003). However, only a few of these evaluations were per-
formed using experimental models of immune-mediated diabetes
(Cvjetic´anin et al., 2010; Sonawane et al., 2010).
We believe that the protective effect of Uncaria tomentosa on
MLDS-induced diabetes was, at least partially, due to a dimin-
ished islet inﬂammatory process. Control mice injected with STZ
presented a pattern of severe insulitis, characterized by the pre-
dominance of moderate to severe insulitis. On  the other hand,
treatment with Uncaria tomentosa extract changed this pattern
by increasing the percentage of intact islets. A reduced frequency
of parameters usually linked to islet disfunction, such as apop-
totic bodies, vacuolization and eosinophilia, was  also observed
after Uncaria tomentosa treatment. Interestingly, the extract also
preserved much of the ability of the islet to produce insulin, as
demonstrated by the in situ immunohistochemistry analysis.
The tight association between pancreatic inﬁltration of the
major orchestrators of -cell damage, such as auto-reactive CD4+
+and CD8 lymphocytes, and destruction of insulin-secreting -cell
was recently reported (Wesley et al., 2010). Immune-mediated
diabetes has been classically described as a predominant Th1 medi-
ated disease, characterized by an elevated production of IFN-
roduction. *Signiﬁcantly different from G1 group, p < 0.05; **Signiﬁcantly different
spectively; G3: MLDS control; G6 and G7: MLDS + Uncaria tomentosa extract at 100
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nd IL-2 in both human patients and experimental models (Csorba
t al., 2010). In this context, it has been assumed that a naturally
redominant or a protocol-induced Th2 proﬁle might avoid or ame-
iorate diabetes manifestations (Muller et al., 2002; Christen and
on Herrath, 2004). In this investigation we also conﬁrmed this
h1 polarization in STZ injected mice by evaluating cytokine pro-
uction in spleen cells stimulated with ConA. Cell cultures from
iabetic mice produced higher IFN- levels than normal animals.
o differences were observed in IL-4 levels. Treatment with Uncaria
omentosa did not modify the high IFN- levels, but the highest
xtract dose signiﬁcantly increased both IL-4 and IL-5 levels. These
esults suggested that the observed protective effect could be due,
t least partially, to a Th2 polarization. In fact, previous studies have
emonstrated the potential of herbal extracts to modulate the inci-
ence and progression of immune-mediated diabetes through the
ynamic modulation of cytokines toward a Th2 proﬁle (Li et al.,
007; Chen et al., 2008).
As CD4+CD25+Foxp3 regulatory T cells (Treg cells) are essen-
ial to maintain self-tolerance (Wan, 2010) and have also been a
romising target in autoimmunity therapy (Hsieh and Bautista,
010), their possible contribution to the protection determined
y Uncaria tomentosa was evaluated. Our data showed that STZ-
iabetic mice presented a signiﬁcant reduction in the percentage
f CD4+CD25+Foxp3 Treg cells in the spleen. Treatment with the
ncaria tomentosa extract restored the number of splenic Treg
ells to values similar to those observed in healthy animals. Our
nterpretation of this data is based on evidences that Treg cells dis-
ocate from secondary lymphoid organs to the target sites to control
he inﬂammatory process (Kim, 2006). We  could ﬁrst hypothe-
ize that natural Treg cells that are usually present in the spleen,
elocated to the pancreas during diabetes to control insulitis. How-
ver, they were not effective due to their small number or low
ctivation status. In this context, we could think that Uncaria tomen-
osa treatment could modulate Treg cell subset by increasing their
umber and activation stage. This could partially control diabetes
nd restore Treg cell number in the spleen. This possibility is, at
ome extension, supported by literature, once the Treg cells have
ndeed been reported to exert control of insulitis in the MLDS model
Zdravkovic et al., 2009). In addition, it was demonstrated in NOD
ice that peripheral Treg cells were able to prevent diabetes by
nitially homing to the pancreas (Lepault and Gagnerault, 2000).
It is important to highlight that this treatment, even at the high-
st extract doses, was not associated with any signs of systemic
r organ-speciﬁc toxicity. These ﬁndings are partially supported
y a previous work that demonstrated a LD50 higher than 8 g/kg
or the low-alkaloid content Uncaria tomentosa aqueous extract
Sheng et al., 2000). Taken together, our results indicate that Uncaria
omentosa was able to protect mice against immune-mediated
iabetes. The immunological assays indicated that this protective
bility could be determined by a Th2 polarization, an expansion
f Foxp3+ Treg cells, or both mechanisms. As this protection was
evoid of any relevant associated deleterious effect, we  believe
hat this extract, or more puriﬁed derivatives, are worthwhile to
e considered in human diabetes treatment and, therefore, should
e extensively studied.
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